Objective

Tisagenlecleucel is a CD19-directed, genetically modified, autologous T-cell immunotherapy indicated for pediatric and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia and for adult patients with relapsed/refractory diffuse large B-cell lymphoma. Treatment with any chimeric antigen receptor (CAR)-T cell therapy is a multistep process in which nurses and nurse practitioners are key to managing patient safety. Managing patients receiving CAR-T cell therapy in the outpatient setting (as Penn does with tisagenlecleucel and lisocabtagene maraleucel) requires an even more complex process. The objective of this manuscript is to provide guidance on the role of nurses in the outpatient administration of tisagenlecleucel therapy and postinfusion care in adult patients with diffuse large B-cell lymphoma. Oncology and apheresis nurses discuss institutional processes and perspectives related to the patient experience with tisagenlecleucel therapy at the Hospital of the University of Pennsylvania.

Data Sources

Author experience.

Conclusion

Nurses are vital for the success of the patient management processes involved with tisagenlecleucel therapy. Nurses must be thoroughly educated in tisagenlecleucel therapy and adverse event management and be able to effectively communicate all aspects of therapy among the multidisciplinary team of the hospital, the product manufacturer, and patients and families. Establishment of the nurse cellular therapy coordinator at the Hospital of the University of Pennsylvania was advantageous in facilitating effective communication in all these situations.

Implications for Nursing

This encompassing approach to patient management is particularly necessary during administration of tisagenlecleucel therapy and other CAR-T cell therapies that are managed in the outpatient setting.

中文翻译：

---

Tisagenlecleucel 疗法：门诊护理的注意事项

客观的

Tisagenlecleucel 是一种 CD19 导向的、转基因的自体 T 细胞免疫疗法，适用于患有复发性/难治性前体 B 细胞急性淋巴细胞白血病的儿童和年轻成人患者以及患有复发性/难治性弥漫性大 B 细胞淋巴瘤的成人患者。任何嵌合抗原受体 (CAR)-T 细胞疗法的治疗都是一个多步骤的过程，护士和执业护士是管理患者安全的关键。管理在门诊接受 CAR-T 细胞治疗的患者（就像 Penn 对 tisagenlecleucel 和 lisocabtagene maraleucel 所做的那样）需要一个更复杂的过程。本手稿的目的是为护士在成人弥漫性大 B 细胞淋巴瘤患者的 tisagenlecleucel 治疗和输注后护理的门诊管理中的作用提供指导。

数据源

作者经历。

结论

护士对于 tisagenlecleucel 治疗所涉及的患者管理过程的成功至关重要。护士必须接受 tisagenlecleucel 治疗和不良事件管理方面的全面教育，并能够在医院、产品制造商、患者和家属的多学科团队之间有效沟通治疗的各个方面。在宾夕法尼亚大学医院设立护士细胞治疗协调员有利于促进所有这些情况下的有效沟通。

对护理的影响

在 tisagenlecleucel 治疗和其他在门诊管理的 CAR-T 细胞治疗期间，这种全面的患者管理方法尤其必要。